Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer

Molecular Therapy — Oncolytics(2020)10.1016/j.omto.2020.08.008Source: DataRank Database

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer is a research paper published in Molecular Therapy — Oncolytics (2020). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

Linked data & code

refseq nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 2.56)OA: goldTopics (29)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Luis E. Muñoz ORCID,Roxana M. Rodríguez Stewart,Periasamy Selvaraj ORCID,Bernardo A. Mainou ORCID,Jameson Berry ORCID

Live enrichment

PubMed:32995480 PMC:PMC7493048 OpenAlex:https://openalex.org/W3080841098

Winship Cancer Institute

Grant: P30CA138292

National Institutes of Health

Grant: R01 AI146260

National Institutes of Health

Grant: R01 CA202763-S

National Institutes of Health

Grant: UL1TR002378

NCI NIH HHS

Grant: R01 CA202763

National Institutes of Health

Grant: 2P30CA138292-04

Winship Cancer Institute Cancer Center Support Grant

National Institutes of Health

Grant: 3R01CA202763-04S1

Membrane-based immunotherapy for triple negative breast cancer- a partnered approach

National Institutes of Health

Grant: 5R01AI146260-05

Development of Oncolytic Reovirus for Triple-Negative Breast Cancer

National Institutes of Health

Grant: 5UL1TR002378-09

Georgia Clinical & Translational Science Alliance (Georgia CTSA)

American Cancer Society

Children's Healthcare of Atlanta

Kaul Pediatric Research Institute

National Cancer Institute

FWCI

2.56

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S237277052030125X/pdf

publisherhttp://www.cell.com/article/S237277052030125X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S237277052030125X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S237277052030125X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.omto.2020.08.008

Fields of Study

Virus-based gene therapy researchViral gastroenteritis research and epidemiologyCancer Research and Treatments0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Oncolytic virusDoxorubicinTriple-negative breast cancerBreast cancerCancer researchMetastatic breast cancerMedicineCancerImmunologyChemotherapyOncologyVirologyInternal medicineDNA damageVirusCell deathreovirusDrug DeliveryVirus-host InteractionsOncolyticsNeoplasms. Tumors. Oncology. Including cancer and carcinogensOriginal ArticleRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 2 of A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

10.6084/m9.figshare.23167760.v1figshare

Additional file 2 of A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

10.6084/m9.figshare.23167760figshare

Additional file 1 of A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

10.6084/m9.figshare.23167757.v1figshare

Additional file 1 of A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy

10.6084/m9.figshare.23167757figshare

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer

FAIR Checklist

Authors (5)

Funding (13 grants)

Impact

Open Access

Topics

Linked Datasets (4)

Annotations (Europe PMC)